Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
39.85
-0.60 (-1.48%)
Jun 4, 2025, 1:42 PM - Market open
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.43M in the quarter ending March 31, 2025, a decrease of -2.14%. This brings the company's revenue in the last twelve months to $10.04M, down -2.04% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$10.04M
Revenue Growth
-2.04%
P/S Ratio
8.91
Revenue / Employee
$123,963
Employees
81
Market Cap
291.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TNXP News
- 13 days ago - Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewsWire
- 14 days ago - Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - GlobeNewsWire
- 22 days ago - Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - GlobeNewsWire
- 7 weeks ago - Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies - GlobeNewsWire